Baxter International Inc (NYSE:BAX) Shares Purchased by Gofen & Glossberg LLC IL

Gofen & Glossberg LLC IL increased its position in shares of Baxter International Inc (NYSE:BAX) by 3.5% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 15,816 shares of the medical instruments supplier’s stock after purchasing an additional 530 shares during the quarter. Gofen & Glossberg LLC IL’s holdings in Baxter International were worth $1,383,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently modified their holdings of the stock. Stonebridge Capital Advisors LLC increased its position in Baxter International by 4.3% during the second quarter. Stonebridge Capital Advisors LLC now owns 2,886 shares of the medical instruments supplier’s stock worth $236,000 after buying an additional 120 shares in the last quarter. SeaCrest Wealth Management LLC increased its position in Baxter International by 2.0% during the second quarter. SeaCrest Wealth Management LLC now owns 6,117 shares of the medical instruments supplier’s stock worth $501,000 after buying an additional 122 shares in the last quarter. Baker Ellis Asset Management LLC increased its position in Baxter International by 8.3% during the second quarter. Baker Ellis Asset Management LLC now owns 1,625 shares of the medical instruments supplier’s stock worth $133,000 after buying an additional 125 shares in the last quarter. Boston Private Wealth LLC increased its position in Baxter International by 1.8% during the second quarter. Boston Private Wealth LLC now owns 7,346 shares of the medical instruments supplier’s stock worth $602,000 after buying an additional 129 shares in the last quarter. Finally, Brookstone Capital Management increased its position in Baxter International by 4.0% during the second quarter. Brookstone Capital Management now owns 3,422 shares of the medical instruments supplier’s stock worth $280,000 after buying an additional 131 shares in the last quarter. 83.44% of the stock is owned by hedge funds and other institutional investors.

In other news, Director James R. Gavin III sold 7,950 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $87.63, for a total transaction of $696,658.50. Following the completion of the sale, the director now owns 40,932 shares in the company, valued at approximately $3,586,871.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jacqueline Kunzler sold 5,934 shares of the stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $88.12, for a total value of $522,904.08. Following the sale, the senior vice president now owns 3,089 shares of the company’s stock, valued at approximately $272,202.68. The disclosure for this sale can be found here. Insiders have sold a total of 14,064 shares of company stock valued at $1,235,359 in the last quarter. Insiders own 0.70% of the company’s stock.

A number of brokerages have recently commented on BAX. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Baxter International in a research report on Tuesday, September 10th. BMO Capital Markets increased their price objective on Baxter International to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 26th. JPMorgan Chase & Co. set a $94.00 price objective on Baxter International and gave the stock a “buy” rating in a report on Tuesday. Barclays set a $82.00 target price on Baxter International and gave the stock a “hold” rating in a research report on Friday, July 26th. Finally, Wells Fargo & Co set a $95.00 target price on Baxter International and gave the stock a “buy” rating in a research report on Friday, July 26th. Five investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $85.67.

BAX opened at $88.03 on Friday. The company has a market capitalization of $44.94 billion, a price-to-earnings ratio of 28.86, a price-to-earnings-growth ratio of 2.01 and a beta of 0.99. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.78 and a quick ratio of 2.10. Baxter International Inc has a 1-year low of $61.05 and a 1-year high of $89.93. The business has a 50 day moving average price of $87.00 and a two-hundred day moving average price of $81.69.

Baxter International (NYSE:BAX) last released its earnings results on Thursday, July 25th. The medical instruments supplier reported $0.89 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.08. Baxter International had a return on equity of 21.21% and a net margin of 14.28%. The firm had revenue of $2.84 billion during the quarter, compared to the consensus estimate of $2.80 billion. During the same period in the prior year, the firm posted $0.77 earnings per share. The firm’s revenue for the quarter was down .1% compared to the same quarter last year. Equities analysts expect that Baxter International Inc will post 3.37 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, October 1st. Stockholders of record on Friday, August 30th were given a dividend of $0.22 per share. The ex-dividend date of this dividend was Thursday, August 29th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 1.00%. Baxter International’s dividend payout ratio (DPR) is presently 28.85%.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Featured Article: Strangles

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.